Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.

A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.

Six years after being diagnosed with B-cell ALL at 21, William Yank opens up about the physical changes of treatment, the emotional weight of constant care and the role hope plays in his survivorship.